Logo image of GMAB

GENMAB A/S -SP ADR (GMAB) Stock Fundamental Analysis

NASDAQ:GMAB - Nasdaq - US3723032062 - ADR - Currency: USD

21.4  -0.46 (-2.1%)

After market: 21.4 0 (0%)

Fundamental Rating

5

GMAB gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. While GMAB belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. GMAB has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

In the past year GMAB was profitable.
GMAB had a negative operating cash flow in the past year.
In the past 5 years GMAB has always been profitable.
GMAB had a positive operating cash flow in each of the past 5 years.
GMAB Yearly Net Income VS EBIT VS OCF VS FCFGMAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

1.2 Ratios

With an excellent Return On Assets value of 36.16%, GMAB belongs to the best of the industry, outperforming 98.75% of the companies in the same industry.
The Return On Equity of GMAB (44.97%) is better than 98.40% of its industry peers.
With an excellent Return On Invested Capital value of 37.15%, GMAB belongs to the best of the industry, outperforming 99.47% of the companies in the same industry.
GMAB had an Average Return On Invested Capital over the past 3 years of 15.19%. This is in line with the industry average of 14.78%.
The last Return On Invested Capital (37.15%) for GMAB is above the 3 year average (15.19%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 36.16%
ROE 44.97%
ROIC 37.15%
ROA(3y)15.85%
ROA(5y)16.41%
ROE(3y)18.38%
ROE(5y)18.67%
ROIC(3y)15.19%
ROIC(5y)16.37%
GMAB Yearly ROA, ROE, ROICGMAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20 25

1.3 Margins

GMAB has a better Profit Margin (29.99%) than 96.98% of its industry peers.
In the last couple of years the Profit Margin of GMAB has declined.
With an excellent Operating Margin value of 33.50%, GMAB belongs to the best of the industry, outperforming 98.04% of the companies in the same industry.
GMAB's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 95.91%, GMAB belongs to the top of the industry, outperforming 95.37% of the companies in the same industry.
In the last couple of years the Gross Margin of GMAB has declined.
Industry RankSector Rank
OM 33.5%
PM (TTM) 29.99%
GM 95.91%
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
GMAB Yearly Profit, Operating, Gross MarginsGMAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

6

2. Health

2.1 Basic Checks

GMAB has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, GMAB has less shares outstanding
GMAB has less shares outstanding than it did 5 years ago.
The debt/assets ratio for GMAB is higher compared to a year ago.
GMAB Yearly Shares OutstandingGMAB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
GMAB Yearly Total Debt VS Total AssetsGMAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.2 Solvency

An Altman-Z score of 43.06 indicates that GMAB is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 43.06, GMAB belongs to the best of the industry, outperforming 98.40% of the companies in the same industry.
GMAB has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of GMAB (0.02) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 43.06
ROIC/WACC5.37
WACC6.92%
GMAB Yearly LT Debt VS Equity VS FCFGMAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.3 Liquidity

A Current Ratio of 5.34 indicates that GMAB has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.34, GMAB is in line with its industry, outperforming 56.23% of the companies in the same industry.
A Quick Ratio of 5.32 indicates that GMAB has no problem at all paying its short term obligations.
GMAB has a Quick ratio of 5.32. This is comparable to the rest of the industry: GMAB outperforms 57.30% of its industry peers.
Industry RankSector Rank
Current Ratio 5.34
Quick Ratio 5.32
GMAB Yearly Current Assets VS Current LiabilitesGMAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

More info and screens

4

3. Growth

3.1 Past

The earnings per share for GMAB have decreased strongly by -35.87% in the last year.
The Earnings Per Share has been growing by 15.75% on average over the past years. This is quite good.
GMAB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -55.29%.
Measured over the past years, GMAB shows a decrease in Revenue. The Revenue has been decreasing by -9.38% on average per year.
EPS 1Y (TTM)-35.87%
EPS 3Y15.53%
EPS 5Y15.75%
EPS Q2Q%-84.89%
Revenue 1Y (TTM)-55.29%
Revenue growth 3Y-26.96%
Revenue growth 5Y-9.38%
Sales Q2Q%-82.74%

3.2 Future

GMAB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.22% yearly.
Based on estimates for the next years, GMAB will show a quite strong growth in Revenue. The Revenue will grow by 11.76% on average per year.
EPS Next Y51.17%
EPS Next 2Y34.57%
EPS Next 3Y30.51%
EPS Next 5Y18.22%
Revenue Next Year15.81%
Revenue Next 2Y15.31%
Revenue Next 3Y14.81%
Revenue Next 5Y11.76%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
GMAB Yearly Revenue VS EstimatesGMAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 10B 20B 30B
GMAB Yearly EPS VS EstimatesGMAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15 20

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 24.88, the valuation of GMAB can be described as rather expensive.
Compared to the rest of the industry, the Price/Earnings ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 94.84% of the companies listed in the same industry.
GMAB's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.41.
With a Price/Forward Earnings ratio of 10.36, the valuation of GMAB can be described as very reasonable.
Based on the Price/Forward Earnings ratio, GMAB is valued cheaper than 96.62% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of GMAB to the average of the S&P500 Index (35.19), we can say GMAB is valued rather cheaply.
Industry RankSector Rank
PE 24.88
Fwd PE 10.36
GMAB Price Earnings VS Forward Price EarningsGMAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

GMAB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. GMAB is cheaper than 93.42% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 29.2
GMAB Per share dataGMAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

GMAB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of GMAB may justify a higher PE ratio.
A more expensive valuation may be justified as GMAB's earnings are expected to grow with 30.51% in the coming years.
PEG (NY)0.49
PEG (5Y)1.58
EPS Next 2Y34.57%
EPS Next 3Y30.51%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GMAB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GENMAB A/S -SP ADR

NASDAQ:GMAB (7/11/2025, 8:18:45 PM)

After market: 21.4 0 (0%)

21.4

-0.46 (-2.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-07 2025-08-07/bmo
Inst Owners35.41%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap13.19B
Analysts77.24
Price Target111.85 (422.66%)
Short Float %0.38%
Short Ratio1.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)92.16%
Min EPS beat(2)49.64%
Max EPS beat(2)134.67%
EPS beat(4)3
Avg EPS beat(4)44.12%
Min EPS beat(4)-11.29%
Max EPS beat(4)134.67%
EPS beat(8)6
Avg EPS beat(8)30.35%
EPS beat(12)8
Avg EPS beat(12)28.68%
EPS beat(16)11
Avg EPS beat(16)28.52%
Revenue beat(2)1
Avg Revenue beat(2)-2.9%
Min Revenue beat(2)-7.66%
Max Revenue beat(2)1.87%
Revenue beat(4)2
Avg Revenue beat(4)-1.37%
Min Revenue beat(4)-7.66%
Max Revenue beat(4)4.57%
Revenue beat(8)6
Avg Revenue beat(8)0.63%
Revenue beat(12)10
Avg Revenue beat(12)2.66%
Revenue beat(16)14
Avg Revenue beat(16)3.42%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-84.64%
EPS NQ rev (3m)-83.59%
EPS NY rev (1m)-0.05%
EPS NY rev (3m)3.21%
Revenue NQ rev (1m)-84.98%
Revenue NQ rev (3m)-85.53%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.77%
Valuation
Industry RankSector Rank
PE 24.88
Fwd PE 10.36
P/S 10.6
P/FCF N/A
P/OCF N/A
P/B 15.9
P/tB 26.44
EV/EBITDA 29.2
EPS(TTM)0.86
EY4.02%
EPS(NY)2.07
Fwd EY9.65%
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS2.02
BVpS1.35
TBVpS0.81
PEG (NY)0.49
PEG (5Y)1.58
Profitability
Industry RankSector Rank
ROA 36.16%
ROE 44.97%
ROCE 45.64%
ROIC 37.15%
ROICexc 83.17%
ROICexgc 439.3%
OM 33.5%
PM (TTM) 29.99%
GM 95.91%
FCFM N/A
ROA(3y)15.85%
ROA(5y)16.41%
ROE(3y)18.38%
ROE(5y)18.67%
ROIC(3y)15.19%
ROIC(5y)16.37%
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)18.66%
ROCE(5y)20.11%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
F-Score6
Asset Turnover1.21
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA 0.05
Cap/Depr 76.79%
Cap/Sales 0.61%
Interest Coverage 8004.34
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.34
Quick Ratio 5.32
Altman-Z 43.06
F-Score6
WACC6.92%
ROIC/WACC5.37
Cap/Depr(3y)96.21%
Cap/Depr(5y)101.76%
Cap/Sales(3y)1.96%
Cap/Sales(5y)2.38%
Profit Quality(3y)107.36%
Profit Quality(5y)103.53%
High Growth Momentum
Growth
EPS 1Y (TTM)-35.87%
EPS 3Y15.53%
EPS 5Y15.75%
EPS Q2Q%-84.89%
EPS Next Y51.17%
EPS Next 2Y34.57%
EPS Next 3Y30.51%
EPS Next 5Y18.22%
Revenue 1Y (TTM)-55.29%
Revenue growth 3Y-26.96%
Revenue growth 5Y-9.38%
Sales Q2Q%-82.74%
Revenue Next Year15.81%
Revenue Next 2Y15.31%
Revenue Next 3Y14.81%
Revenue Next 5Y11.76%
EBIT growth 1Y-53.2%
EBIT growth 3Y-28.52%
EBIT growth 5Y-16.38%
EBIT Next Year31.35%
EBIT Next 3Y25.55%
EBIT Next 5Y13.52%
FCF growth 1Y-101.46%
FCF growth 3Y-16.81%
FCF growth 5Y-1.31%
OCF growth 1Y-100.64%
OCF growth 3Y-19%
OCF growth 5Y-2.24%